Abstract
The prevalence of chronic renal disease is increasing dramatically in industrialized nations. Recent surveys in Europe and the US show that about 10% of the total population are affected. Patients with end stage disease, necessitating dialysis or transplantation, are only the tip of the iceberg. Even with treatment these subjects suffer from a massive reduction in quality and quantity of life despite consuming a large proportion of healthcare expenditures. As quite effective treatment strategies are available to prevent progression there is a pressing clinical need for early detection, differential diagnosis and assessment of the individual prognosis of renal disease. The current gold standard is the measurement of serum creatinine; despite the fact this method has some major limitations. These can be partially overcome by the use of newer markers like Cystatin C. However, a major problem using this approach is the fact that serum creatinine and Cystatin C are markers of renal excretory function only and hence no differential diagnosis can be derived from them. Furthermore a single measurement is not sufficient to estimate the prognosis of an individual patient, especially in the early stages of the disease, making tailored treatment difficult. In this review we will summarize our current knowledge about the markers in use today and also provide information on new, potentially superior markers, which would enable a much more complete non-invasive assessment of a growing patient population.
Keywords: Chronic kidney disease, biomarkers, glomerular filtration rate, serum creatinine, proteinuria, tubulointerstitial damage
Current Medicinal Chemistry
Title: In Search for the Troponin of the Kidney
Volume: 16 Issue: 32
Author(s): S-J. Noppert and G. Mayer
Affiliation:
Keywords: Chronic kidney disease, biomarkers, glomerular filtration rate, serum creatinine, proteinuria, tubulointerstitial damage
Abstract: The prevalence of chronic renal disease is increasing dramatically in industrialized nations. Recent surveys in Europe and the US show that about 10% of the total population are affected. Patients with end stage disease, necessitating dialysis or transplantation, are only the tip of the iceberg. Even with treatment these subjects suffer from a massive reduction in quality and quantity of life despite consuming a large proportion of healthcare expenditures. As quite effective treatment strategies are available to prevent progression there is a pressing clinical need for early detection, differential diagnosis and assessment of the individual prognosis of renal disease. The current gold standard is the measurement of serum creatinine; despite the fact this method has some major limitations. These can be partially overcome by the use of newer markers like Cystatin C. However, a major problem using this approach is the fact that serum creatinine and Cystatin C are markers of renal excretory function only and hence no differential diagnosis can be derived from them. Furthermore a single measurement is not sufficient to estimate the prognosis of an individual patient, especially in the early stages of the disease, making tailored treatment difficult. In this review we will summarize our current knowledge about the markers in use today and also provide information on new, potentially superior markers, which would enable a much more complete non-invasive assessment of a growing patient population.
Export Options
About this article
Cite this article as:
Noppert S-J. and Mayer G., In Search for the Troponin of the Kidney, Current Medicinal Chemistry 2009; 16 (32) . https://dx.doi.org/10.2174/092986709789578150
DOI https://dx.doi.org/10.2174/092986709789578150 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry Evaluation and Management of Asymptomatic Bradyarrhythmias
Current Cardiology Reviews Vascular Damage in Obesity and Diabetes: Highlighting Links Between Endothelial Dysfunction and Metabolic Disease in Zebrafish and Man
Current Vascular Pharmacology Gene Delivery for Periodontal Tissue Engineering: Current Knowledge – Future Possibilities
Current Gene Therapy Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Resolution of Type 2 Diabetes with Reduction in Body Mass Index Using Meal Replacement Based Weight Loss
Vascular Disease Prevention (Discontinued) Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Recent Clinical Aspects of Eating Disorders
Reviews on Recent Clinical Trials Effect of Experimental Stenosis on the Vibration of the Porcine Aortic Wall
Vascular Disease Prevention (Discontinued) Meet the Editorial Board Member
Current Drug Targets miR-135a Suppresses Calcification in Senescent VSMCs by Regulating KLF4/STAT3 Pathway
Current Vascular Pharmacology An Integrated In Silico Method to Discover Novel Rock1 Inhibitors: Multi- Complex-Based Pharmacophore, Molecular Dynamics Simulation and Hybrid Protocol Virtual Screening
Combinatorial Chemistry & High Throughput Screening Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications
Current Pharmaceutical Design Integrin Signaling Networks in the Pathobiology of Vascular Smooth Muscle Cells
Vascular Disease Prevention (Discontinued) Management of Patients with Poly-Vascular Disease: Priorities for Revascularization Procedures
Current Vascular Pharmacology Admission, 24 Hours and Discharge Troponin T Among Acute Myocardial Infarction Patients: Differing by Prognostic Contribution
Recent Patents on Biomarkers